Prevention Of Recurrence Of Atrial Fibrillation

• Status: Completed
• Trial end date: 2003-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Symptomatic persistent atrial fibrillation requiring DC cardioversion.

• Duration of AF >48 hrs. <6 months

Exclusion Criteria:

• Concomitant Class I and/or III anti-arrhythmic drugs.

• Amiodarone treatment within 3 months of the study.

• Other inclusion or exclusion criteria to be determined by the physician and study sponsor.